MedTrace Logo

Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia

NCT00099528 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2010-07-29

No results posted yet for this study

Summary

The purpose of this study is to gain initial safety and efficacy data on the experimental agent REN-1654 in patients with painful post-herpetic neuralgia (PHN).

Conditions

  • Neuralgia
  • Shingles
  • Peripheral Nervous System Disease

Interventions

DRUG

REN-1654

Sponsors & Collaborators

  • Renovis

    lead INDUSTRY

Principal Investigators

  • Randall W Moreadith, MD, PhD · Chief Medical Officer, Renovis, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Completion
2004-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00099528 on ClinicalTrials.gov